← Back to Search

Alkalinizing Agent

Sodium Bicarbonate Tablets for Cognitive Impairment

Phase < 1
Waitlist Available
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 12 months
Awards & highlights

Study Summary

This trial is testing whether sodium bicarbonate can improve cognitive and cerebrovascular function in patients with CKD stage 3b-4 who have metabolic acidosis.

Eligible Conditions
  • Cognitive Impairment
  • Metabolic Acidosis
  • Chronic Kidney Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Cognitive Function at 12 months
Change in Cognitive Function composite score at 12 months
Change in Crystallized cognition composite score at 12 months
+1 more
Secondary outcome measures
Change in Cerebrovascular hemodynamics at 12 months

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Sodium bicarbonateExperimental Treatment1 Intervention
Sodium bicarbonate will be used at a dose of 0.5 mEq/kg-lean body weight/day.
Group II: PlaceboPlacebo Group1 Intervention
Placebo medication will be used at a dose of 0.5 mEq/kg-lean body weight/day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sodium Bicarbonate Tablets
2021
Completed Early Phase 1
~40

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,749 Previous Clinical Trials
2,164,026 Total Patients Enrolled
~8 spots leftby May 2025